Press Release

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--May 31, 2018--
TransEnterix, Inc. (NYSE American:TRXC), a medical device company that
is digitizing the interface between the surgeon and the patient to
improve minimally invasive surgery, today announced that LSU Health
completed the purchase of the Company’s Senhance™ Surgical
System. The Senhance has been installed at University Medical Center New
Orleans (UMC New Orleans).

UMC New Orleans is home to the Reverend Avery C. Alexander Academic
Research Hospital, and is an academic medical center in partnership with
LSU Health New Orleans, Tulane University School of Medicine, and other
local colleges and universities. UMC New Orleans will be a center for
clinical excellence utilizing the Senhance Surgical System in general,
colorectal and gynecologic surgery.

The Senhance Surgical System represents an innovative technology
designed to assist surgeons in performing minimally invasive surgery.
While seated comfortably at a console, the surgeon uses multiple robotic
arms to control small surgical instruments with robotic precision while
at the same time moving a small scope that tracks the eye movement of
the surgeon. The Senhance is the first surgical robotic system to offer
the security of haptic force feedback that allows surgeons to feel the
forces the instruments generate when handling delicate tissue.

“We are pleased that LSU Health New Orleans is beginning its digital
laparoscopy program using the Senhance Surgical system,” said Todd M.
Pope, President and CEO at TransEnterix. “Our system is designed to
support responsible economics for the hospital, and we look forward to
partnering with the surgeons at UMC New Orleans to advance patient care
in ways that matter in today's value-based healthcare landscape.”

“LSU Health New Orleans and University Medical Center New Orleans see
the Senhance Surgical System as an important and necessary advance in
surgical care,” said Dr. Guy Orangio FACS, FASCRS, Chief Section of
Colorectal Surgery at LSU Health New Orleans, and President of the
American Society of Colon and Rectal Surgeons. “This new robotic system
brings enabling technology with haptic feedback and innovative surgeon
camera control while minimizing costs and maintaining existing
efficiencies.”

“Patients are seeking minimally invasive options that utilize the most
advanced technology to treat gynecologic conditions,” said Dr. Lisa M.
Peacock, Chairperson of the Department of Obstetrics and Gynecology, and
Section Head and Program Director of Female Pelvic Medicine and
Reconstructive Surgery at LSU Health New Orleans. ”As an academic
medical center, we believe this new robotic surgical platform will play
an important role in our continued leadership in surgical teaching,
research, and providing excellent patient care.”

On May 29, 2018, TransEnterix announced that it received FDA 510(k)
clearance for laparoscopic inguinal hernia and laparoscopic
cholecystectomy (gallbladder removal) procedures, doubling its total
addressable market in the U.S. to over three million annual procedures.
In the U.S., Senhance is now cleared for laparoscopic colorectal,
gynecologic, inguinal hernia and cholecystectomy surgery.

About TransEnterix

TransEnterix is a medical device company that is digitizing the
interface between the surgeon and the patient to improve minimally
invasive surgery by addressing the clinical and economic challenges
associated with current laparoscopic and robotic options in today's
value-based healthcare environment. The Company is focused on the
commercialization of the Senhance Surgical System, which digitizes
laparoscopic minimally invasive surgery. The system allows for robotic
precision, haptic feedback, surgeon camera control via eye sensing and
improved ergonomics while offering responsible economics. The Senhance
Surgical System is available for sale in the US, the EU and select other
countries. For more information, visit www.transenterix.com.

About University Medical Center New Orleans

Opened in August 2015, University Medical Center New Orleans is the
academic medical center of LCMC Health, a Louisiana-based,
not-for-profit health system. UMC New Orleans serves as a key partner of
LSU Health Science Center New Orleans, Tulane University School of
Medicine and other academic institutions. UMC is home to the Rev. Avery
C. Alexander Academic Research Hospital, named in honor of the respected
Civil Rights and community leader who served in the Louisiana
Legislature for more than 20 years.

Forward-Looking Statements

This press release includes statements relating to the Senhance
Surgical System and our current regulatory and commercialization plans
for this product. These statements and other statements regarding our
future plans and goals constitute "forward looking statements" within
the meaning of Section 27A of the Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934, and are intended to qualify for
the safe harbor from liability established by the Private Securities
Litigation Reform Act of 1995. Such statements are subject to risks and
uncertainties that are often difficult to predict, are beyond our
control and which may cause results to differ materially from
expectations and include whether TransEnterix’s partnering with the
surgeons at UMC New Orleans will advance patient care in ways that
matter in today’s value-based healthcare landscape and whether the
Senhance Surgical Robotic System will play an important role in UMC New
Orleans’ continued leadership in surgical teaching, research, and
providing excellent patient care.For a discussion of the risks
and uncertainties associated with TransEnterix's business, please review
our filings with the Securities and Exchange Commission (SEC), including
our Annual Report on Form 10-K filed on March 8, 2018 and our other
filings we make with the SEC. You are cautioned not to place undue
reliance on these forward looking statements, which are based on our
expectations as of the date of this press release and speak only as of
the origination date of this press release. We undertake no obligation
to publicly update or revise any forward-looking statement, whether as a
result of new information, future events or otherwise.